As of September 09, 2026, Black Diamond Therapeutics's top three insider holders are Ali Behbahani (Director, 4.45Mn shares), Venture Capital Vi, L.P. Versant (TenPercentOwner, 3.73Mn shares), Venture Capital Vi, L.P. Versant (TenPercentOwner, 3.73Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Venture Capital Vi, L.P. Versant | TenPercentOwner | 3,726,341 | 0 | 3,726,341 | 46.9% | 30 Aug, 2024 |
| 2 | Growth N V Biotech | TenPercentOwner | 2,733,547 | 0 | 2,733,547 | 34.4% | 20 Mar, 2025 |
| 3 | David M. Epstein | Director, Officer | 671,423 | 0 | 671,423 | 8.5% | 28 Jun, 2023 |
| 4 | Elizabeth Buck | Chief Scientific Officer | 170,192 | 0 | 170,192 | 2.1% | 31 Jan, 2025 |
| 5 | Fang Ni | Officer | 125,389 | 0 | 125,389 | 1.6% | 23 Dec, 2022 |
| 6 | Mark A. Velleca | President Ceo | 121,522 | 0 | 121,522 | 1.5% | 31 Jan, 2025 |
| 7 | Ali Behbahani | Director | 93,568 | 0 | 93,568 | 1.2% | 20 Mar, 2026 |
| 8 | Erika Jones | Officer | 85,150 | 0 | 85,150 | 1.1% | 31 Jan, 2025 |
| 9 | Brent Hatzis-Schoch | Officer | 83,400 | 0 | 83,400 | 1.1% | 31 Jan, 2025 |
| 10 | Sergey Yurasov | Chief Medical Officer | 75,000 | 0 | 75,000 | 0.9% | 31 Jan, 2025 |
| 11 | Prakash Raman | Director | 45,039 | 0 | 45,039 | 0.6% | 22 Jun, 2026 |
| 12 | Shannon Campbell | Director | 8,865 | 0 | 8,865 | 0.1% | 16 Dec, 2024 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 26 Jun, 2026 | Prakash Raman | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 26 Jun, 2026 | Kapil Dhingra | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 26 Jun, 2026 | Garry E Menzel | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 26 Jun, 2026 | Shannon Campbell | Director | Acquired A | 40,000 | $0.00 | $0 | 40,000 | Direct |
| 19 Jun, 2026 | Prakash Raman | Director | Acquired A | 7,907 | $1.66 | $13.13K | 45,039 | Direct |
| 20 Mar, 2026 | Ali Behbahani | Director | Acquired A | 6,919 | $2.15 | $14.88K | 93,568 | Direct |
| 20 Mar, 2026 | Prakash Raman | Director | Acquired A | 6,105 | $2.15 | $13.13K | 37,132 | Direct |
| 21 Jan, 2026 | Sergey Yurasov | Chief Medical Officer | Acquired A | 250,000 | $0.00 | $0 | 250,000 | Direct |
| 21 Jan, 2026 | Mark A. Velleca | President Ceo | Acquired A | 600,000 | $0.00 | $0 | 600,000 | Direct |
| 21 Jan, 2026 | Brent Hatzis-Schoch | Officer | Acquired A | 250,000 | $0.00 | $0 | 250,000 | Direct |
| 21 Jan, 2026 | Sergey Yurasov | Chief Medical Officer | Acquired A | 250,000 | $0.00 | $0 | 250,000 | Direct |
| 21 Jan, 2026 | Erika Jones | Officer | Acquired A | 200,000 | $0.00 | $0 | 200,000 | Direct |
| 21 Jan, 2026 | Sergey Yurasov | Chief Medical Officer | Acquired A | 250,000 | $0.00 | $0 | 250,000 | Direct |
| 21 Jan, 2026 | Elizabeth Buck | Chief Scientific Officer | Acquired A | 250,000 | $0.00 | $0 | 250,000 | Direct |
| 21 Jan, 2026 | Erika Jones | Officer | Acquired A | 200,000 | $0.00 | $0 | 200,000 | Direct |
| 21 Jan, 2026 | Mark A. Velleca | President Ceo | Acquired A | 600,000 | $0.00 | $0 | 600,000 | Direct |
| 21 Jan, 2026 | Elizabeth Buck | Chief Scientific Officer | Acquired A | 250,000 | $0.00 | $0 | 250,000 | Direct |
| 21 Jan, 2026 | Elizabeth Buck | Chief Scientific Officer | Acquired A | 250,000 | $0.00 | $0 | 250,000 | Direct |
| 21 Jan, 2026 | Mark A. Velleca | President Ceo | Acquired A | 600,000 | $0.00 | $0 | 600,000 | Direct |
| 21 Jan, 2026 | Erika Jones | Officer | Acquired A | 200,000 | $0.00 | $0 | 200,000 | Direct |